Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

Autoimmune play Enthera first biotech to emerge from Italy’s BiovelocITA accelerator

U.S. and European investors are backing the largest-ever series A financing for an Italian biotech, autoimmune play Enthera s.r.l.

Enthera raised €28 million ($32.8 million) in the round, which was led by existing investor Sofinnova Partners and new investor AbbVie Ventures.

Italy has historically lacked a dedicated venture

Read the full 479 word article

How to gain access

Continue reading with a
two-week free trial.